FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’" is generating significant coverage in the Business category, with 10 articles from 9 distinct sources tracked by PULSE so far.
Outlets currently covering the story include BioWorld News, Managed Healthcare Executive, Medscape and MedPage Today. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 43d ago.
Quick answers
Why is "FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’" trending?
Because 9 independent news sources published 10 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- Otsuka’s Simtriyo nod: Qelbree vs. three in ADHD? BioWorld News · 45d ago
- FDA approves Simtriyo, the first triple reuptake inhibitor for ADHD Managed Healthcare Executive · 45d ago
- FDA Approves First NDSRI for ADHD in Adults and Children Medscape · 45d ago
- First-in-Class Drug for ADHD Wins FDA Approval MedPage Today · 45d ago
- Otsuka’s Simtriyo nod: Qelbree vs. three in ADHD? BioWorld News · 45d ago
- FDA Approves Simtriyo Pharmaceutical Executive · 45d ago
- Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD FirstWord Pharma · 45d ago
- Otsuka’s ADHD approval opens up new drug class with $615M opportunity BioSpace · 45d ago
- FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults Psychiatric Times · 45d ago
- FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’ Fierce Pharma · 45d ago
Topics
Related trends
Salmonella Outbreak That Sickened 22 Is Linked to Broccoli Sprouts From Idaho
Broccoli sprouts from Idaho linked to a multi-state salmonella outbreak that sickened 22 people and led to recalls.
What to know about the new mRNA flu vaccine
The FDA has approved Moderna's first mRNA-based flu vaccine, introducing a first-of-its-kind shot specifically for adults over the age of 50.
The Newest COVID Shot Is Here — Doctors Suggest The Best Time To Get It For The Most Protection
The FDA has approved four updated COVID-19 vaccines for the 2026-2027 season, now available at major U.S. pharmacy chains.
FDA names acting heads of drug and vaccine centers to permanent roles
The Trump administration has transitioned acting leaders of the FDA's drug and vaccine centers into permanent leadership roles.
Dog supplements recalled over potential salmonella contamination
Pet supplements sold on major platforms face recalls due to potential salmonella risks.
Cream Cheese recalled after listeria detected by FDA
Made Fresh Salads has issued a recall for cream cheese and deli-style salads in New York City following the FDA's detection of Listeria.